BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.

Olivier J van Not,Willeke A M Blokx,Alfons J M van den Eertwegh,Melissa M de Meza,John B Haanen,Christian U Blank,Maureen J B Aarts,Franchette W P J van den Berkmortel,Jan Willem B de Groot,Geke A P Hospers,Ellen Kapiteijn,Djura Piersma,Rozemarijn S van Rijn,Marion Stevense-den Boer,Astrid A M van der Veldt,Marye J Boers-Sonderen,Anne M L Jansen,Michel W J M Wouters,Karijn P M Suijkerbuijk

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 4|浏览3

暂无评分

摘要

Ipilimumab-nivolumab-treated patients with -mutant melanoma display improved PFS and OS compared with patients with -mutant and double wild-type melanoma. mutation status is a factor to consider while choosing between mono and dual checkpoint inhibition in advanced melanoma.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要